NIFTY PHARMA Index PE Ratio
NIFTY PHARMA Index PE Ratio. The NIFTY PHARMA P/E ratio is 51.72 on a market cap weighted basis, derived from the price-to-earnings data of 20 of 20 index constituents with valid EPS. Of these, 1 stocks trade at a low P/E ratio below 15, 2 at moderate valuations between 15 and 25, 12 at elevated earnings multiples between 25 and 50, and 5 at very high valuations above 50. Analyse NIFTY PHARMA earnings growth to understand aggregate earnings trends across constituents. Use the NIFTY PHARMA PE ratio screener below to analyse the historical valuation trend, EPS distribution, and stock-level price-to-earnings data across all 20 constituents.
NIFTY PHARMA PE Ratio Distribution — Low, Moderate, High & Very High
1 low (<15), 2 moderate (15–25), 12 high (25–50), 5 very high (50+) among 20 NIFTY PHARMA stocks. For live index level, EPS data and the full index overview, see NIFTY PHARMA constituents list.
NIFTY PHARMA PE Ratio Historical Trend — 6 Years
Market cap weighted P/E of NIFTY PHARMA over 6 years — 20 stocks with valid EPS, current P/E 51.72. Check NIFTY PHARMA market capitalization to monitor the combined market capitalisation of all constituents.
NIFTY PHARMA Component Stocks — P/E Ratio & EPS
20 of 20 NIFTY PHARMA constituents with valid P/E — sorted by market cap weight.
| Company | Sector | Market Cap | EPS | PE Ratio |
|---|---|---|---|---|
|
SUNPHARMA
Sun Pharmaceutical
|
Healthcare | ₹4.3 Lakh Cr | ₹47.80 | 36.0 |
|
DIVISLAB
Divis Laboratories
|
Healthcare | ₹2.4 Lakh Cr | ₹96.75 | 84.4 |
|
TORNTPHARM
Torrent Pharmaceuticals
|
Healthcare | ₹1.9 Lakh Cr | ₹63.92 | 90.1 |
|
ZYDUSLIFE
Zydus Life Science
|
Healthcare | ₹1.1 Lakh Cr | ₹50.09 | 24.9 |
|
LAURUSLABS
Laurus Labs
|
Healthcare | ₹1.1 Lakh Cr | ₹16.47 | 97.3 |
|
CIPLA
Cipla
|
Healthcare | ₹1.1 Lakh Cr | ₹48.03 | 32.3 |
|
MANKIND
Mankind Pharma
|
Healthcare | ₹1.0 Lakh Cr | ₹46.35 | 49.5 |
|
DRREDDY
Dr Reddys Laboratories
|
Healthcare | ₹1.0 Lakh Cr | ₹50.41 | 31.7 |
|
AUROPHARMA
Aurobindo Pharma
|
Healthcare | ₹96.5K Cr | ₹60.34 | 26.0 |
|
LUPIN
Lupin
|
Healthcare | ₹92.0K Cr | ₹116.75 | 16.8 |
|
GLENMARK
Glenmark Pharmaceuticals
|
Healthcare | ₹64.8K Cr | ₹48.26 | 36.7 |
|
ALKEM
Alkem Laboratories
|
Healthcare | ₹62.7K Cr | ₹192.51 | 28.1 |
|
BIOCON
Biocon
|
Healthcare | ₹60.3K Cr | ₹2.82 | 144.9 |
|
ABBOTINDIA
Abbott
|
Healthcare | ₹55.5K Cr | ₹730.36 | 34.4 |
|
GLAND
Gland Pharma
|
Healthcare | ₹49.6K Cr | ₹62.35 | 42.6 |
|
IPCALAB
IPCA Laboratories
|
Healthcare | ₹49.3K Cr | ₹44.98 | 35.6 |
|
AJANTPHARM
Ajanta Pharma
|
Healthcare | ₹43.6K Cr | ₹84.53 | 39.4 |
|
JBCHEPHARM
J B Chemicals and Pharmaceuticals
|
Healthcare | ₹40.2K Cr | ₹45.16 | 56.3 |
|
GRANULES
Granules
|
Healthcare | ₹20.3K Cr | ₹24.47 | 33.8 |
|
NATCOPHARM
Natco Pharma
|
Healthcare | ₹16.1K Cr | ₹79.20 | 14.1 |
Track NIFTY PHARMA PE Analysis in Your Trading Journal
Use this PE ratio analysis to evaluate index valuation and make informed trading decisions. Monitor how PE trends affect your position sizing and market timing strategies.
Add NIFTY PHARMA Trade to Journal